TRACER-Transformative Rare Cancer Initiative

The Transformative Rare Cancer initiative (TRACER) at Fred Hutchinson Cancer Center is dedicated to overcoming the unique challenges posed by rare cancers, which, although individually uncommon, collectively account for over 20% of global cancer diagnoses. TRACER's mission is structured around four key pillars: 1. Engaging the Community: Building strong connections among clinicians, researchers, nonprofits, and patient advocates to foster collaboration and support for rare cancer patients. 2. Developing Valuable Research Resources: Creating and sharing advanced preclinical models, such as new cell lines and patient-derived xenografts, to facilitate the assessment of therapeutic agents and deepen understanding of rare cancer mechanisms. 3. Building a Data-Rich Resource Platform: Establishing a comprehensive system for collecting and analyzing rare tumor data to identify potential therapeutic targets and biomarkers, thereby enhancing treatment strategies. 4. Partnering with FDA and Clinical Trial Specialists: Collaborating with regulatory bodies and clinical experts to translate laboratory discoveries into effective clinical applications, accelerating the development of novel therapies for rare cancer patients. Through these concerted efforts, TRACER aims to transform the landscape of rare cancer research and treatment, ultimately improving outcomes for affected individuals.